Welcome to our dedicated page for Merit Med Sys news (Ticker: MMSI), a resource for investors and traders seeking the latest updates and insights on Merit Med Sys stock.
Merit Medical Systems Inc. develops, manufactures and distributes proprietary medical devices used in interventional, diagnostic and therapeutic procedures, with product activity concentrated in cardiology, radiology, oncology, critical care and endoscopy. Company news commonly covers operating results, annual guidance, revenue presentation by Foundational and Therapeutic product categories, and portfolio actions involving acquired or divested device lines.
Recurring updates also include commercial launches and distribution arrangements for products such as the Resilience Through-the-Scope Esophageal Stent, ViaVerte basivertebral nerve ablation system, OneMark Detection Imaging System and OneMark Tissue Markers. Governance announcements and healthcare conference participation appear alongside financial and product disclosures.
Merit Medical (NASDAQ: MMSI) will participate in the Bank of America 2026 Health Care Conference in Las Vegas, May 12-14, 2026. Management will hold a fireside chat on Tuesday, May 12 at 3:00 PM PT / 6:00 PM ET.
A live audio webcast will be available under the company’s Events section and a replay will remain accessible for approximately 90 days.
Merit Medical Systems (NASDAQ: MMSI) reported Q1 2026 revenue of $381.9M (+7% reported; +5% constant currency; +3% organic) and GAAP EPS of $0.68 (up 39%). Non-GAAP EPS was $0.94 (up 9%), free cash flow was $24.7M (up 26%), and non-GAAP operating margin improved to 19.7%. Merit sold the DualCap product assets for $28M and acquired View Point Medical for $140M (paid $90M cash at closing). Full-year 2026 revenue guidance is $1.612–$1.634B; acquisition expected to add $2–$4M revenue and dilute non-GAAP EPS by ~$0.05.
Merit Medical (NASDAQ: MMSI) will release first quarter 2026 financial results after market close on Thursday, April 30, 2026. The company will hold an investor conference call the same day at 4:30 p.m. ET with a live webcast and slide deck available online.
Investors may pre-register for dial-in details; registration and webcast links will be posted at www.merit.com. Merit develops and distributes proprietary medical devices and employs about 7,600 people with over 800 sales and clinical support staff worldwide.
Merit Medical (NASDAQ: MMSI) acquired View Point Medical via merger, making View Point a Merit subsidiary effective April 1, 2026. The aggregate consideration is approximately $140 million including assumed liabilities, with $90 million paid at closing and two deferred $25 million payments.
Merit expects 2026 revenue contribution of $2M–$4M, 2027 contribution of $14M–$16M, near-term non‑GAAP EPS dilution of $0.05, and projects OneMark sales to grow ≥20% annually with ~70% non‑GAAP gross margins.
Medtronic entered a distribution agreement with Merit Medical Systems (NASDAQ: MMSI) to offer the FDA-cleared ViaVerte™ basivertebral nerve ablation (BVNA) system.
ViaVerte is a minimally invasive, implant-free, physician-steerable BVNA system for chronic vertebrogenic lower-back pain; it will be available later in 2026 and expands Medtronic's pain interventions portfolio.
Merit Medical (NASDAQ: MMSI) announced the US commercial launch of the Resilience Through-the-Scope (TTS) Esophageal Stent on March 16, 2026. The stent is indicated for esophageal fistulas and malignant strictures and features proprietary anti-migration flanges, a single-handed deployment system, and unique sizes 14x50, 17x50, and 20x50 mm to address placement and migration challenges.
Merit Medical (NASDAQ: MMSI) reported fourth-quarter revenue of $393.9M (up 11%) and fiscal 2025 revenue of $1.516B (up 12%). GAAP EPS was $2.13 for 2025; non-GAAP EPS was $3.83 (up 11%). Free cash flow for 2025 was $215.7M (up 16%).
The company provided fiscal 2026 guidance of $1.61B–$1.63B revenue (+6%–8%) and non-GAAP EPS of $4.01–$4.15 (+5%–8%), and reported cash of $446.4M with total debt of $747.5M as of December 31, 2025.
Merit Medical (NASDAQ: MMSI) announced that the Board appointed F. Ann Millner as Chair of the Board effective January 5, 2026, following Fred P. Lampropoulos’ resignation as director and Chair on January 4, 2026. Lampropoulos will provide consulting services through March 31, 2026.
Merit reported preliminary unaudited Q4 2025 revenue of $389 million to $395 million, up approximately 10%–11% year‑over‑year. Preliminary constant currency revenue rose about 8%–10%, with a foreign exchange impact of $(4.4) million. Merit will release full Q4 and FY2025 results and fiscal 2026 guidance after market close on February 24, 2026 and hold a conference call at 4:30 p.m. ET.
Merit Medical (NASDAQ: MMSI) will participate in the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, January 12-15, 2026. Management will present a company overview on Tuesday, January 13, 2026 at 4:30 PM PT / 7:30 PM ET.
Martha G. Aronson, President and CEO, and Raul Parra, CFO, will deliver the presentation. A live audio webcast will be accessible via Merit’s investor relations "Events" page, and presentation materials will be posted to Merit’s investor relations "Investor Events and Presentations" page. A replay will be available on the site for approximately 90 days.
Merit Medical (NASDAQ: MMSI) said CMS has deferred consideration of its Transitional Pass-Through incremental payment application for the WRAPSODY® Cell-Impermeable Endoprosthesis (CIE) to the CY 2027 Outpatient Prospective Payment System, making Jan 1, 2027 the earliest possible effective date. Merit has withdrawn the TPT application and will begin full U.S. commercialization immediately. The company reiterated a 2025 U.S. revenue forecast of $2 million to $4 million for WRAPSODY CIE and cited 24-month efficacy results from its WRAPSODY WAVE Trial as a commercial differentiator. The device has FDA PMA (Dec 19, 2024), Health Canada approval (Apr 30, 2025), CE mark, and availability in Brazil.